Abivax’s obefazimod met primary endpoint in Phase III ABTECT trial

Abivax has reported that the Phase III ABTECT maintenance trial of obefazimod met the primary endpoint in adults with moderately to severely active UC. The results showed obefazimod met the FDA primary endpoint of placebo-adjusted clinical remission at week 44. Abivax plans to submit a new drug application to the FDA in late fourth quarter 2026. Credit: PaeGAG / Shutterstock.com. Abivax has reported that the Phase III ABTECT maintenance trial of obefazimod, its investigational oral, first-in-class miR-124 enhancer, met the primary endpoint in adults with moderately to severely active ulcerative colitis (UC). The double-blind, global, multi-centre, placebo-controlled, randomised trial assessed…

Source: Clinical Trials Arena